**Question:** Which of the following anticancer drugs causes hemolytic uremic syndrome?

**Core Concept:** Hemolytic uremic syndrome (HUS) is a rare complication that occurs in response to certain medications or infections. It is characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury.

**Why the Correct Answer is Right:** Hemolytic uremic syndrome is mainly caused by the use of some anticancer drugs, particularly those in the alkylating agent family. These drugs target DNA synthesis and repair, leading to genomic instability, which can trigger HUS.

**Why Each Wrong Option is Incorrect:**

A. Option A (unknown): This option does not specify a particular anticancer drug, so we cannot determine why it is wrong in this context. However, it is essential to understand that not all alkylating agents cause HUS, and the correct answer explains why this particular drug is associated with HUS.

B. Option B (unknown): Similar to Option A, this option does not mention the specific drug causing HUS. Alkylating agents can cause HUS, but not all of them do, and the correct answer clarifies the specific drug and its mechanism.

C. Option C (unknown): As with Options A and B, this option is too vague to determine why it is incorrect. However, the correct answer explains the mechanism of HUS induced by the correct answer drug.

D. Option D (cyclophosphamide): Cyclophosphamide is an alkylating agent and can cause HUS. The correct answer explains the specific mechanism by which cyclophosphamide triggers HUS.

**Clinical Pearl:** Hemolytic uremic syndrome is a serious complication that can occur with the use of certain alkylating agents like cyclophosphamide. It is crucial for medical professionals to be aware of these complications and monitor patients receiving these medications for signs and symptoms of HUS.

**Correct Answer:** Cyclophosphamide is the correct answer as it is an alkylating agent that can cause hemolytic uremic syndrome (HUS). Cyclophosphamide interferes with DNA synthesis and repair, leading to genomic instability. This instability can result in the activation of the complement system, causing endothelial cell damage and subsequent HUS.

**Explanation:** Cyclophosphamide, a cytotoxic chemotherapeutic drug, is an alkylating agent that interferes with DNA synthesis and repair, leading to genomic instability. This instability triggers the activation of the complement system, which results in endothelial cell damage and the development of HUS.

**Clinical Pearls:**

1. Alkylating agents like cyclophosphamide can cause HUS.
2. Monitor patients receiving these medications for signs and symptoms of HUS.
3. Understanding the mechanism by which alkylating agents induce HUS allows for early recognition and intervention when needed.